MktsMarkets

Fate Therapeutics, Inc.
NASDAQ: FATEKey statistics
FATE News
Stories mentioning FATE from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1,299 | 1,369 | 1,741 | 1,907 | 1,629 | 1,860 | 3,074 | 6,772 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 24,703 | 25,425 | 25,838 | 27,430 | 29,136 | 33,609 | 34,650 | 34,604 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 34,299 | 36,090 | 36,476 | 38,875 | 42,909 | 63,608 | 55,451 | 51,855 |
| Operating Income (Loss) | (33,000) | (34,721) | (34,735) | (36,968) | (41,280) | (61,748) | (52,377) | (45,083) |
| Interest Income | 1,867 | 2,220 | 2,575 | 2,921 | 3,336 | 3,874 | 4,438 | 4,827 |
| Interest Expense | ||||||||
| Other Expense | 1,787 | 2,347 | 2,485 | 2,898 | 3,659 | 9,595 | 4,699 | 6,656 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (31,213) | (32,374) | (32,250) | (34,070) | (37,621) | (52,153) | (47,678) | (38,427) |
| Earnings Per Share (Basic) | (0.26) | (0.27) | (0.27) | (0.29) | (0.32) | (0.46) | (0.40) | (0.33) |
| Earnings Per Share (Diluted) | (0.26) | (0.27) | (0.27) | (0.29) | (0.32) | (0.46) | (0.40) | (0.33) |
| Weighted Average Shares Outstanding (Basic) | 120,031 | 118,790 | 118,999 | 118,528 | 118,376 | 113,685 | 117,769 | 117,468 |
| Weighted Average Shares Outstanding (Diluted) | 120,031 | 118,790 | 118,999 | 118,528 | 118,376 | 113,685 | 117,769 | 117,468 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About FATE
Fate Therapeutics, Inc. (NASDAQ: FATE) is a stock listed on the Nasdaq Stock Market under the ticker symbol FATE. It last traded at $2.17 (Oct 29, 2026, 4:00 PM ET), unchanged on the day. That gives Fate Therapeutics a market capitalisation of $260.0M.
Over the past 52 weeks FATE has traded between $0.9500 and $3.23.
Revenue for the quarter ended Mar 31, 2026 was $1.3M; a net loss of $31.2M. Revenue was down 20.3% from $1.6M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $1.3M | -$31.2M | -2402.8% |
| Dec 31, 2025 | $1.4M | -$32.4M | -2364.8% |
| Sep 30, 2025 | $1.7M | -$32.3M | -1852.4% |
| Jun 30, 2025 | $1.9M | -$34.1M | -1786.6% |
From Fate Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…